Cargando…
The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial
BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the e...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506247/ https://www.ncbi.nlm.nih.gov/pubmed/34729060 http://dx.doi.org/10.4103/jrms.JRMS_579_19 |
_version_ | 1784581698078375936 |
---|---|
author | Karimifard, Maryam Aminorroaya, Ashraf Amini, Massoud Kachuie, Ali Feizi, Awat Yamini, Sima Aminorroaya Alijanvand, Moluk Hadi |
author_facet | Karimifard, Maryam Aminorroaya, Ashraf Amini, Massoud Kachuie, Ali Feizi, Awat Yamini, Sima Aminorroaya Alijanvand, Moluk Hadi |
author_sort | Karimifard, Maryam |
collection | PubMed |
description | BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the effects of bisphosphonates on lipid profile including triglyceride (TG), total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) of prediabetic postmenopausal women with osteopenia. MATERIALS AND METHODS: In this triple-blind randomized controlled trial, sixty prediabetic, postmenopausal women with sufficient Vitamin D and osteopenia, aged 45–60 years, were randomly enrolled in two groups of intervention (receiving 70-mg alendronate for 12 weeks [duration for maximum metabolic effect of bisphosphonates], n = 30) and control (receiving placebo, n = 30) according to a randomized block procedure of size 2 and 1:1 allocation ratio. The primary outcome of the study, the lipid profile, was evaluated before and after the interventions. The effect of the intervention was assessed using analysis of covariance. RESULTS: The lipid profiles showed no significant differences to the mean values at the baseline in both the groups (all P > 0.05). At the end of the study, the differences between the groups were not significant for 25(OH) D(3) (mean difference: −11.09, 95% confidence interval: −32.43–10.25), T (4.19, −30.58–38.97), cholesterol (8.13, −13.07–29.33), LDL-cholesterol (5.07, −10.18–20.31), and HDL-cholesterol (−0.86, −6.04–4.31) when the baseline values and confounders were adjusted (all P > 0.05). CONCLUSION: No statistically significant difference was detected in the serum lipid profile of prediabetic postmenopausal women with osteopenia as a result of alendronate intervention. More studies with larger sample sizes and longer intervention periods are recommended. |
format | Online Article Text |
id | pubmed-8506247 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-85062472021-11-01 The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial Karimifard, Maryam Aminorroaya, Ashraf Amini, Massoud Kachuie, Ali Feizi, Awat Yamini, Sima Aminorroaya Alijanvand, Moluk Hadi J Res Med Sci Original Article BACKGROUND: Prediabetes is a high-risk state for developing diabetes at an annual rate of 5%–10%. Early intervention can prevent further complications, including metabolic syndrome. Bisphosphonates are commonly used for osteoporotic postmenopausal women. The purpose of this study was to assess the effects of bisphosphonates on lipid profile including triglyceride (TG), total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) of prediabetic postmenopausal women with osteopenia. MATERIALS AND METHODS: In this triple-blind randomized controlled trial, sixty prediabetic, postmenopausal women with sufficient Vitamin D and osteopenia, aged 45–60 years, were randomly enrolled in two groups of intervention (receiving 70-mg alendronate for 12 weeks [duration for maximum metabolic effect of bisphosphonates], n = 30) and control (receiving placebo, n = 30) according to a randomized block procedure of size 2 and 1:1 allocation ratio. The primary outcome of the study, the lipid profile, was evaluated before and after the interventions. The effect of the intervention was assessed using analysis of covariance. RESULTS: The lipid profiles showed no significant differences to the mean values at the baseline in both the groups (all P > 0.05). At the end of the study, the differences between the groups were not significant for 25(OH) D(3) (mean difference: −11.09, 95% confidence interval: −32.43–10.25), T (4.19, −30.58–38.97), cholesterol (8.13, −13.07–29.33), LDL-cholesterol (5.07, −10.18–20.31), and HDL-cholesterol (−0.86, −6.04–4.31) when the baseline values and confounders were adjusted (all P > 0.05). CONCLUSION: No statistically significant difference was detected in the serum lipid profile of prediabetic postmenopausal women with osteopenia as a result of alendronate intervention. More studies with larger sample sizes and longer intervention periods are recommended. Wolters Kluwer - Medknow 2021-08-30 /pmc/articles/PMC8506247/ /pubmed/34729060 http://dx.doi.org/10.4103/jrms.JRMS_579_19 Text en Copyright: © 2021 Journal of Research in Medical Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Karimifard, Maryam Aminorroaya, Ashraf Amini, Massoud Kachuie, Ali Feizi, Awat Yamini, Sima Aminorroaya Alijanvand, Moluk Hadi The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title | The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title_full | The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title_fullStr | The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title_full_unstemmed | The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title_short | The effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: A randomized triple-blind clinical trial |
title_sort | effect of alendronate on lipid profile of postmenopausal women with osteopenia and prediabetes: a randomized triple-blind clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506247/ https://www.ncbi.nlm.nih.gov/pubmed/34729060 http://dx.doi.org/10.4103/jrms.JRMS_579_19 |
work_keys_str_mv | AT karimifardmaryam theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT aminorroayaashraf theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT aminimassoud theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT kachuieali theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT feiziawat theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT yaminisimaaminorroaya theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT alijanvandmolukhadi theeffectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT karimifardmaryam effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT aminorroayaashraf effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT aminimassoud effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT kachuieali effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT feiziawat effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT yaminisimaaminorroaya effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial AT alijanvandmolukhadi effectofalendronateonlipidprofileofpostmenopausalwomenwithosteopeniaandprediabetesarandomizedtripleblindclinicaltrial |